Amgen has invested in Carmot Therapeutics having previously licensed a cancer drug candidate from the company that is currently in phase 2 clinical trials.
US-based metabolic disease medicine developer Carmot Therapeutics has received $47m in a series C round backed by pharmaceutical firm Amgen.
The round also featured venture capital firm Horizons Ventures, healthcare-focused VC fund Column Group and unnamed institutional investors.
Carmot is developing treatments for metabolic diseases such as type 2 diabetes, obesity and fatty liver disease. Its lead drug candidate, CT-868, targets two pancreatic receptors – GLP-1 and GIP – associated with producing incretin, the hormone responsible for modulating blood glucose…
